Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Sutro Biopharma, Inc. reported a quarterly loss of $0.89 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.86, and a significant decline from earnings of $0.42 per share a year ago, indicating an earnings surprise of -3.49% [1] - The company posted revenues of $14 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 34.11%, but this represents a decline from year-ago revenues of $113.72 million [2] - Over the last four quarters, Sutro Biopharma has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Sutro Biopharma shares have declined approximately 27.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.86 on $15 million in revenues, and for the current fiscal year, it is -$2.95 on $61.38 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Sutro Biopharma belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]